<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03575403</url>
  </required_header>
  <id_info>
    <org_study_id>44796</org_study_id>
    <nct_id>NCT03575403</nct_id>
  </id_info>
  <brief_title>Behavioral Effects of Drugs: Inpatient (36) (Alcohol, Duloxetine, and Methylphenidate)</brief_title>
  <acronym>BED IN 36</acronym>
  <official_title>A Novel Drug Combination for Alcohol-Use Disorders: A Human Laboratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Craig Rush</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the behavioral effects of alcohol during maintenance on placebo,
      duloxetine, methylphenidate and duloxetine combined with methylphenidate using sophisticated
      human laboratory methods.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reinforcing Effects</measure>
    <time_frame>After at least six days of placebo, duloxetine or methylphenidate maintenance</time_frame>
    <description>The reinforcing effects of alcohol will be determined using a self-administration procedure in which subjects choose to take previously sampled doses. Reinforcing effects are measured during maintenance on placebo, duloxetine and methylphenidate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scales of Alcohol Effects</measure>
    <time_frame>4 sessions over approximately 4 weeks of study participation</time_frame>
    <description>Subjects will complete measures using visual analog scales rated from 0-100 to report alcohol effects during three sessions while they are admitted to the inpatient unit. These items will ask about alcohol effects. Higher scores indicate greater effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breath Alcohol Level</measure>
    <time_frame>4 sessions over approximately 4 weeks of study participation</time_frame>
    <description>Breath alcohol level will be recorded during three sessions while subjects are admitted to the inpatient unit. Breath alcohol level will be recorded in percent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>4 sessions over approximately 4 weeks of study participation</time_frame>
    <description>Systolic blood pressure will be recorded during three sessions while subjects are admitted to the inpatient unit. Systolic blood pressure will be recorded in mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>4 sessions over approximately 4 weeks of study participation</time_frame>
    <description>Diastolic blood pressure will be recorded during three sessions while subjects are admitted to the inpatient unit. Diastolic blood pressure will be recorded in mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>4 sessions over approximately 4 weeks of study participation</time_frame>
    <description>Heart rate will be recorded during three sessions while subjects are admitted to the inpatient unit. Heart rate will be recorded in beats per minute.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive oral placebo capsules one time daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Duloxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 30 mg oral duloxetine one time daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Duloxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 60 mg oral duloxetine one time daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alcohol</intervention_name>
    <description>In each arm, subjects will receive doses of alcohol, designed to raise BALs to 0.015 and 0.03 g/dl.</description>
    <arm_group_label>High Dose Duloxetine</arm_group_label>
    <arm_group_label>Low Dose Duloxetine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Subjects will receive placebo capsules.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Subjects will receive duloxetine capsules.</description>
    <arm_group_label>High Dose Duloxetine</arm_group_label>
    <arm_group_label>Low Dose Duloxetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate</intervention_name>
    <description>Subjects will receive methylphenidate capsules.</description>
    <arm_group_label>High Dose Duloxetine</arm_group_label>
    <arm_group_label>Low Dose Duloxetine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  able to speak/read English

          -  not seeking treatment at the time of the study

          -  one binge drinking episode (5+/4+ standard alcoholic drinks per drinking session for
             men and women, respectively) in the past 30 days

          -  recent alcohol use verified by ethyl glucuronide positive urine, as well as
             fulfillment of DSM-5 diagnostic criteria for alcohol use disorder

          -  ECG within normal limits

          -  otherwise healthy

          -  body mass index of 19-35

          -  females using an effective form of birth control and not pregnant or breast feeding

          -  judged by the medical staff to be psychiatrically and physically healthy

          -  able to abstain from alcohol for 12 hours prior to session

          -  no contraindications/allergies to duloxetine or methylphenidate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Rush, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frances Wagner, RN</last_name>
    <phone>859-257-5388</phone>
    <email>fpwagn2@uky.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frances Wagner, RN</last_name>
      <phone>859-257-5388</phone>
      <email>fpwagn2@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Craig Rush, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2018</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Craig Rush</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

